Skip to main content

ADVERTISEMENT

Grace Halupnik, MD

Original Contribution
05/11/2022
The Auryon 355-nm laser atherectomy system (AngioDynamics, Inc) showed a low rate of target-lesion revascularization (TLR) at 6-month follow-up in the investigational device exemption study. At present, real-world data are not available. The...
The Auryon 355-nm laser atherectomy system (AngioDynamics, Inc) showed a low rate of target-lesion revascularization (TLR) at 6-month follow-up in the investigational device exemption study. At present, real-world data are not available. The...
The Auryon 355-nm laser...
05/11/2022
Journal of Invasive Cardiology